中国临床药理学杂志2025，Vol.41Issue(15)：2183-2186,4.DOI:10.13699/j.cnki.1001-6821.2025.15.015
间变性淋巴瘤激酶突变阳性非小细胞肺癌患者经鼻胃管接受阿来替尼治疗的病例分析
Successful treatment of an anaplastic lymphoma kinase mutation-positive non-small-cell lung cancer patient with alectinib via nasogastric tube
邢晓清 1杨路 2杨婧怡 3滕珈瑄 4刘维 5曹宝山2
作者信息
- 1. 北京大学第三医院,药学部,北京 100191||河北省人民医院药学部,河北石家庄 050051
- 2. 北京大学第三医院,肿瘤化疗与放射病科,北京 100191||北京大学第三医院,罕见病诊治中心,北京 100191
- 3. 北京大学第三医院,药学部,北京 100191||北京大学药学院药事管理与临床药学系 北京 100191
- 4. 北京市海淀医院/北京大学第三医院海淀院区药学部,北京 100080
- 5. 北京大学第三医院,药学部,北京 100191
- 折叠
摘要
Abstract
Anaplastic lymphoma kinase(ALK)inhibitors have become the standard treatment for patients with advanced non-small cell lung cancer(NSCLC)harboring ALK gene fusion.Due to the variable oral absorption,ALK inhibitors must be swallowed whole,and it is not recommended to open the capsule shell,crush,or dissolve the drug prior to administration.However,for patients unable to take the medication whole,the feasibility of administering ALK inhibitors via a nasogastric tube remains uncertain.Additionally,it is unclear whether oral administration of a crushed alectinib suspension affects bioavailability or therapeutic efficacy.To address these gaps,we report a case of ALK fusion-positive NSCLC managed with nasogastric administration of alectinib,and therapeutic drug monitoring was employed to optimize dosing,ultimately achieving tumor remission.关键词
阿来替尼/非小细胞肺癌/鼻胃管/药物代谢动力学/治疗药物监测Key words
alectinib/nasogastric tube/non-small lung cancer/pharmacokinetics/therapeutic drug monitoring分类
医药卫生引用本文复制引用
邢晓清,杨路,杨婧怡,滕珈瑄,刘维,曹宝山..间变性淋巴瘤激酶突变阳性非小细胞肺癌患者经鼻胃管接受阿来替尼治疗的病例分析[J].中国临床药理学杂志,2025,41(15):2183-2186,4.
